The demand for endometriosis treatment in USA is projected to grow from USD 1.4 billion in 2025 to USD 2.3 billion by 2035, at a CAGR of 5.1%. Oral Contraceptives will dominate with a 45.7% market share, while hormonal therapy will lead the treatment type segment segment with a 75.0% share.